|ILLINOIS MEDICAL ONCOLOGY SOCIETY
Reception for IMOS Members:
Fellows Research Competition Dinner
IMOS Annual Membership Conference:
For more information, go to www.imos-illinois.com
(as of 3/30/12)
Thank you for the value you bring to IMOS!
— Spring 2012 —
As this is my initial column for the Illinois Medical Oncology Society (IMOS) newsletter, I would like to thank you for demonstrating your faith in me by supporting my election to President. It is my pleasure to have the opportunity and honor to work with you and our colleagues to advance the goals of oncology through our organization in the state of Illinois.
A major goal of mine during the next two years will be to raise the profile of IMOS. Although most cancer care professionals are aware that while the American Society of Clinical Oncology, the American Society of Hematology, and other national organizations lead efforts to influence public health policy as it relates to the practice of hematology and oncology, many do not appreciate the advantages of joining and actively participating in a statewide society.
In 2011, IMOS sponsored the State Society Education Series, which marked its inaugural year with four exciting education programs. Now IMOS is planning timely and relevant programs for 2012, starting with an issue that is growing in importance to many of us in the practice of oncology.
Watch for a podcast series coming soon called "Physician Service Agreements: Evolving Models." Listen to our podcasts at your convenience to gain the different perspectives of four oncology professionals who have experienced creating physician service agreements in the oncology community.
WPS Announces Recent Changes to Edits to Monitor High Dollar Claims
WPS Updates Certain Medicare Policies for March 2012
As a Regular, Group, or Associate member of IMOS, you may access the resources of the Association of Community Cancer Centers (ACCC). To view ACCC's digital edition of the 2012 Patient Assistance and Reimbursement Guide, which brings together information on pharmaceutical and non-pharmaceutical patient assistance programs and reimbursement resources, click here. You will need to create a password and log in.
The FDA approved new indications for Prolia® (denosumab) (Amgen, www.amgen.com) as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor (AI) therapy for breast cancer and as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy (ADT) for non-metastatic prostate cancer. In patients with prostate cancer, Prolia also reduced the incidence of vertebral fractures. Denosumab is a monoclonal antibody that binds to RANKL, a protein involved in the formation, function, and survival of osteoclasts, the cells responsible for bone resorption.
For more information about Illinois Medical Oncology Society (IMOS)
You are receiving this message because you are affiliated with IMOS and we believe you will benefit from this information.